Frontlight ResearchEarly access
WithdrawnNo phase
Mucopolysaccharidosis Type II Observational
Key facts
- Who runs it
- REGENXBIO Inc.
- Where
- Oakland and Philadelphia, United StatesSee the 2 sitesAlso in 1 other country, 1 site
- Trial code
- Status
- Withdrawn
- Started
- Mar 2022
- Ended
- Jul 2025
- Type of study
- Observational
- Treatments tested
- Observational
- Record updated
- 10 October 2022
- Why it stopped
- Sponsor decision
Who can take part
- Age
- 1 month to 8 years
- Sex
- Men only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Meets any of the following criteria:; Has a clinical diagnosis of severe MPS II and has a documented mutation in IDS, OR; Has a relative clinically diagnosed with severe MPS II who has the same IDS mutation as the subject, OR; Has documented mutation(s) in IDS that in the opinion of the investigator is known to result in a neuronopathic phenotype
- Has sufficient communication capacity to complete the required protocol testing; Patient's legal guardian must be willing and able to provide written, signed informed consent
Who cannot take part
- Has had prior treatment with an AAV-based gene therapy product
- Is currently participating in a clinical trial of an investigational product for the treatment of MPS II with the exception of IT ELAPRASE trials; no investigational product may be taken starting 30 days or 5 half-lives of the investigational product prior to signing the ICF, whichever is longer
Where in United States
Also in 1 other country, 1 site
- University of California San Francisco, Benioff Children's HospitalOakland, United States
- Children's Hospital of PhiladelphiaPhiladelphia, United States
About the trial
What the trial wants to find out
This is an observational study planned to document prospectively disease manifestation and neurocognitive course in pediatric patients with a clinical presentation consistent with neuronopathic ("severe") MPS II undergoing current standard of care and/or intrathecal Elaprase® for their condition. Some patients may be offered the opportunity to screen for a gene therapy study conducted by the same sponsor.
The group in the trial
- Observational
No Intervention
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Prospective, Observational Study of Pediatric Patients With Neuronopathic Forms of MPS II (Hunter Syndrome)
- Record updated
- 10 October 2022